LetterLetter
Onset of Inflammatory Eye Disease Under Tocilizumab Treatment for Rheumatologic Conditions: a Paradoxical Effect?
DANIEL WENDLING, EMMANUELLE DERNIS, CLÉMENT PRATI, ERIC FRISCH and BERNARD DELBOSC
The Journal of Rheumatology October 2011, 38 (10) 2284; DOI: https://doi.org/10.3899/jrheum.110170
DANIEL WENDLING
MD, PhD
EMMANUELLE DERNIS
MD
CLÉMENT PRATI
MD
ERIC FRISCH
MD
REFERENCES
- 1.↵
- Pham T,
- Claudepierre P,
- Constantin A,
- de Bandt M,
- Fautrel B,
- Gossec L,
- et al.
- 2.↵
- 3.↵
- Wendling D,
- Paccou J,
- Flipo RM,
- Dernis E,
- Direz G,
- Ferrazzi V,
- et al.
- 4.↵
- Gaujoux-Viala C,
- Giampietro C,
- Gaujoux T,
- Ea HK,
- Orcel P,
- Lioté F
- 5.↵
- 6.↵
- 7.↵
- 8.↵
- Yoshimura T,
- Sonoda KH,
- Ohguro N,
- Ohsugi Y,
- Ishibashi T,
- Cua DJ,
- et al.
- 9.↵
- Simon D,
- Denniston AK,
- Tomlins PJ,
- Wallace GR,
- Rauz S,
- Salmon M,
- et al.
- 10.↵
- Hume EB,
- Cole N,
- Garthwaite LL,
- Khan S,
- Willcox MD
In this issue
The Journal of Rheumatology
Vol. 38, Issue 10
1 Oct 2011
Onset of Inflammatory Eye Disease Under Tocilizumab Treatment for Rheumatologic Conditions: a Paradoxical Effect?
DANIEL WENDLING, EMMANUELLE DERNIS, CLÉMENT PRATI, ERIC FRISCH, BERNARD DELBOSC
The Journal of Rheumatology Oct 2011, 38 (10) 2284; DOI: 10.3899/jrheum.110170